Introducing Jesse Ahrendt, Antheia’s SVP of Quality Assurance & Regulatory Affairs
We’ve recently welcomed Jesse Ahrendt, our new Senior Vice President of Quality Assurance and Regulatory Affairs, who will lead our...
top of page
Search
Antheia
- Nov 20, 2022
Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production
In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency...
Antheia
- Aug 25, 2022
Demystifying Synthetic Biology Part V: The Product is Key in Downstream Processing
Dive into DSP in the final edition of our Demystifying SynBio series. If you’re just joining us, be sure to catch up on parts I, II, III,...
Antheia
- Jul 18, 2022
Demystifying Synthetic Biology IV: Fermentation Bioprocess Development
Learn more about synbio and the tools and technologies advancing this field in Part I, Part II, and Part III of this blog series....
Antheia
- Feb 9, 2022
Demystifying Synthetic Biology: Building with the power of biology
Technology today is defined by superlatives: we have the fastest cars, the best medicine, and the most advanced communication tools ever...
Antheia
- Apr 6, 2021
Fixing essential medicine shortages: obstacles and opportunities
Global health experts and governing bodies agree that everyone has a right to access the medicines they need. The COVID-19 pandemic and...
Kristy Hawkins
- Mar 22, 2021
Investing in the next wave of biomanufacturing technologies for pharma
The global pandemic has brought pharmaceutical manufacturing to the forefront of America’s public consciousness. Acute drug shortages...
Kristy Hawkins
- Jan 12, 2021
Scaling synthetic biology as a manufacturing platform
How Antheia is reaching commercial scale with plant-inspired pharmaceuticals
Antheia
- Dec 17, 2020
Meet the Team - Our Engineer, Yuki Higa
For the next installation in the “Meet the Team” series, we hear from Yuki Higa, a Process Engineer at Antheia. Read on to learn about...
Christina Smolke
- Oct 13, 2020
Antheia at SynBioBeta 2020
Earlier this month, my cofounder Kristy Hawkins and I presented at SynBioBeta 2020, the flagship conference for the synthetic biology...
Antheia
- Oct 6, 2020
Meet the Team - Our Scientist, Ken Takeoka
As a part of our new “Meet the Team” series, we hear from Ken Takeoka, Antheia’s very first employee and a Scientist III. Read on to...
Christina Smolke
- Sep 2, 2020
A Milestone for Drug Manufacturing and Synthetic Biology: Stanford Research Published in Nature
It’s a momentous day for my research team at Stanford University. Today, we’ve announced a new paper published in Nature that describes...
Christina Smolke
- Aug 20, 2020
Three plant-based pharmaceuticals: taxol, scopolamine and buprenorphine
Over the last 150 years, the pharmaceutical industry has focused on decoupling the production of medicinal compounds from their sources...
Christina Smolke
- Jul 16, 2020
As Featured in STAT: The pharma supply chain is broken. Synthetic biology could fix it.
COVID-19 has exposed the frailties of the international pharma supply chain and as the pandemic continues to spread, we are seeing the mount
Christina Smolke
- Jun 4, 2020
Modern Medicine’s Ancient Roots
For thousands of years, communities across cultures and geographies have relied on the inherent healing properties of plants. Ancient...
Antheia Newsroom
bottom of page